Human Papillomavirus and Pregnancy (HPVandPregn)
Recruitment status was Recruiting
Purpose Our study involves two hypotheses. One is that genital infection with HPV is associated with increased risk of miscarriage and preterm birth. The second hypothesis is that human papillomavirus can ascend from the vagina to the uterus through the cervix and cross the placental barrier. We wish to verify these hypotheses in our studies.
This study will determine the prevalence of HPV in Danish pregnant women and examine HPV's role in the aetiology of spontaneous abortion and preterm birth.
HPV-infection in Pregnant Women
|Study Design:||Observational Model: Case Control
Time Perspective: Cross-Sectional
|Official Title:||Human Papillomavirus and Pregnancy|
- Human Papillomavirus infection of the uterine cervix in early pregnancy [ Time Frame: 1st of November 2015 ] [ Designated as safety issue: No ]Description of the prevalence of HPV in Danish pregnant women.
- Presence of Human Papillomavirus in uteri in the second trimester of pregnancy [ Time Frame: 1st of November 2015 ] [ Designated as safety issue: No ]Can HPV be found in the placenta during early pregnancy if the woman has HPV-infection on the ectocervix
- Human Papillomavirus infection in the cervix uteri in pregnant women at term [ Time Frame: 1st of November 2015 ] [ Designated as safety issue: No ]The prevalence of HPV in Danish pregnant women at term
- HPV infection and preterm birth [ Time Frame: 1st of November 2015 ] [ Designated as safety issue: No ]Does HPV-infection in the cervix uteri increase the risk of preterm birth?
- HPV infection and miscarriage [ Time Frame: 1st of November 2015 ] [ Designated as safety issue: No ]Does HPV infection increase the risk of miscarriage?
Biospecimen Retention: Samples With DNA
|Study Start Date:||November 2011|
|Estimated Study Completion Date:||November 2015|
|Estimated Primary Completion Date:||November 2014 (Final data collection date for primary outcome measure)|
Women in early pregnancy at around the time of the nuchal translucency scan. The prevalence of HPV will be determined
Chorionic villous sampling
Women undergoing chorionic villous sampling for the purpose of prenatal diagnostics.
Women with miscarriage at a gestational age up to 22 weeks
Women with spontaneous preterm birth/premature primary rupture of membranes at a gestational age week 22-32
Vaginal delivery at term
Women with spontaneous vaginal delivery at term (week 37+0-)
Elective ceaserean section at term
Women undergoing elective cesarean section at term (week 37+0-)
Background Studies have shown significantly higher prevalence of HPV in tissue from miscarriages (60%) than from induced abortions (20%). HPV-infection in the extravillous trophoblasts in the placenta has furthermore been shown to induce cell death and cause dysfunction of the placenta, which can lead to adverse outcome of the pregnancy, e.g. preterm birth and hereby related neonatal mortality and morbidity. Spontaneous abortion and preterm birth are adverse events of the pregnancy, with for the biggest part unknown aetilogy, an area worth trying to elucidate by means of research.
Method 6 groups of each 91 women will be included:
- A group of early pregnant women at the nuchal translucency scan around gestational week 12 and a similar group undergoing chorion villous sampling in relation to prenatal diagnostics of the fetus
- A group of women with spontaneous abortion before gestational week 22 and a group with preterm birth gestational week 22-32
- A group delivering spontaneously at term and a group undergoing elective cesarean at term
The women will be examined by cervical swab to analyze for and do a genotyping of HPV if present. A vaginal swab will be done for the purpose of vaginal microbiome examination later. Furthermore analysis for HPV in placental tissue from chorion villous sampling or evacuation of the uterus after miscarriage. Cervical swabs and placental tissue will be analyzed by means of PCR (polymerase chain reaction) for the 35 types of HPV most frequently found in the anogenital area. Blood samples will be collected from all the patients and analyzed for HPV-antibodies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01897129
|Contact: Ulla B van Zwol, Doctor||+45 firstname.lastname@example.org|
|Department of Gynecology and Obstetrics||Recruiting|
|Odense, Funen, Denmark, 5000|
|Contact: Ulla B van Zwol, Doctor +45022622676 email@example.com|
|Principal Investigator: Ulla B van Zwol, Doctor|
|Study Chair:||Jan S Joergensen, Doctor||Supervisor|